Minocycline/disodium edetate/ethyl alcohol

Drug Profile

Minocycline/disodium edetate/ethyl alcohol

Alternative Names: HEAL solution; Mino-Lok Therapy (MLT); Mino-Lok™; Minocycline-EDTA-EtOH

Latest Information Update: 24 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Class Anti-infectives; Antibacterials; Anticoagulants; Antiseptics; Disinfectants; Small molecules; Tetracyclines
  • Mechanism of Action Chelating agents; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Catheter infections

Most Recent Events

  • 01 Jun 2017 University of Texas M. D. Anderson Cancer Center has a published patent application for enhanced stability of minocycline/disodium edetate/ethyl alcohol in USA
  • 23 Mar 2017 Citius Pharmaceuticals acquires license for minocycline/disodium edetate/ethyl alcohol in South America
  • 19 Dec 2016 Citius Pharmaceuticals submits drug master file to the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top